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APPLICATION NOTE 
Simultaneous Analysis of 14 Non-steroidal 
Anti-Inflammatory Drugs in Human Serum by 
Electrospray Ionization-Tandem Mass 
Spectrometry Without Chromatography 
John de Kanel, William E. Vickery, and Francis X. Diamond 
National Medical Services, Inc., Willow Grove, Pennsylvania, USA 
A method is described for the simultaneous analysis of 14 non-steroidal nti-inflammatory 
drugs (NSAIDS) in human serum using negative electrospray ionization-tandem ass 
spectrometry (ESI-MS/MS). After addition of internal standard and protein precipitation 
using acetonitrile, samples were transferred to autosampler vials for direct analysis without 
chromatography. Injection of an air bubble with the sample and a multiple reaction monitoring 
(MRM) method using argon collision-induced issociation (CID) of analyte (M-H) ions 
permitted integration of the product ion peak areas to produce reproducible quantitative data 
over the range of concentrations expected in serum during routine use of these drugs. The  
method permitted the analysis of 30 samples per hour. Two hundred fifty consecutive analyses 
did not adversely affect instrument sensitivity. (J Am Soc Mass Spectrom 1998, 9, 
255-257) © 1998 American Society for Mass Spectrometry 
N 
on-steroidal anti-inflannnatory drugs (NSAIDS) 
are among the most commonly used pharma- 
ceutical products. Their ubiquitous availability 
makes them a variable that must be controlled for in the 
evaluation of effectiveness of some new drugs. As part 
of a contract o monitor patients involved in clinical 
trials, a rapid exclusion screen for these drugs was 
needed. The use of aspirin could be monitored rapidly 
by immunoassay of salicylate but traditional high per- 
formance liquid chromatography [1,2] or gas chroma- 
tography [3] methods for multiple NSAIDS require 
extraction and more than 30 min per sample for reliable 
separation. Methods using gas chromatography/mass 
spectrometry [4-7], capillary electrophoresis/mass 
spectrometry [8], and liquid chromatography/mass 
spectrometry [9] have been described. 
Experimental 
NSAID sources are given in Table 1. High-pressure 
liquid chromatography (HPLC) grade acetonitrile 
(CH3CN), methanol, n-propanol, and concentrated re- 
agent grade ammonium hydroxide (NH4OH) were pur- 
chased from Fisher Scientific (Fairlawn, NJ). Reagent 
grade sodium iodide (NaI) and cesium iodide (CsI) 
were purchased from Aldrich (Milwaukee, WI). Blank 
serum, purchased from Quality Assurance Services 
Address reprint requests to John de Kanel, Mlalytical Associates, Inc., PO 
Box 61227, King of Prussia, PA 19406. 
Corp. (Augusta, GA), was evaluated for the presence of 
NSAIDS prior to use. Water was prepared with a 
Solution 2000 cartridge deionization unit (Solution Con- 
sultants, Jasper, GA). 
Standards were dissolved in, and diluted with, meth- 
anol before use in spiking blank serum or mobile phase 
to the desired concentration. The CHBCN/n-propanol 
solvent was prepared by mixing 954 mL of acetonitrile 
with 46 mL of n-propanol. Dilute, 0.015-M, NH4OH was 
prepared aily from concentrated NH4OH. The mobile 
phase consisting of 30% CHBCN/n-propanol solvent 
and 70% dilute NH4OH , used to transfer samples from 
the autosampler to the MS/MS, was mixed and deliv- 
ered at 80/~L/min by the quaternary gradient pumping 
system as needed. 
A Hewlett Packard (Santa Clara, CA) model 1100 
liquid chromatograph with G1313A autosampler was 
connected irectly to the MS/MS with approximately 
0.5-m (poly 1,4-phenylene ether ketone (PEEK)) tubing 
with an internal diameter of 0.05 mm. The autosampler 
injection program was modified to include an 8-/zL air 
bubble before the 8.0-/zL sample injection using the 
Hewlett Packard (HP) software provided. Quantitation 
and identification were accomplished using a Micro- 
mass (Altrincham, Cheshire, UK) Quattro II MS/MS 
system operated in the negative lectrospray ionization 
(ESI) mode using MassLynx, version 2.3 software, with- 
out modification. The ion spray voltage was set to 2.2 
kV. The curtain and nebulizer nitrogen flow were 
optimized to 300 and 17 L/h, respectively. The source 
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Table 1. Analyte multiple reaction monitoring parameters and method precision 
Within run Between run 
Orifice Collision Normal range precision precision 
Product potential energy in serum RSD% RSD% 
Compound ion (V) (eV) (/~g/mL) (/~g/mL)" (#g/mL) ~ 
Ketorolac t romethamine (SC) 210 9 7 0.87-3.0 [11] 5.5 (1.0) 5.8 (1.0) 
6-MNA nabumetone metabolite (SB) 156 12 18 26-60 [12] 3.3 (1,0) 9.8 (2.5) 
Tolmetin sodium (MP) 212 6 5 3 .9~9 [13] 9.0 (1.0) 9.7 (2.5) 
Piroxicam (SC) 146 23 15 1.5-3.0 [14] 7.8 (1.0) 6.9 (1.0) 
Naproxen (SC) 170 18 16 31-69 [15, 16] 9.3 (1.0) 11 (2.5) 
Ketoprofen (SC) 209 13 6 1.9-20 [17, 18] 5.4 (1.0) 14 (1.0) 
Flurbiprofen (U) 199 9 6 8.0-9.4 [19] 8.8 (1.0) 9.9 (2.5) 
Ibuprofen (SC) 161 12 6 17~9 [20,×21] 9.8 (1,0) 13 (1.0) 
Etodolac (SC) 242 32 16 12-21 [22, 23) 5.7 (1.0) 4.4 (1.0) 
Diclofenac sodium (SC) 250 20 11 0.75-2.0 [24] 8.5 (1.0) 19 (1.0) 
Indomethacin (SC) 312 15 8 0.3-2.7 [25] 11 (2.5) 7.6 (2.5) 
Mefenamic acid (SC) 196 21 16 4-20 [26] 5.3 (1.0) 8.1 (1.0) 
Fenoprofen calcium (EL) 197 12 7 23-50 [27] 8.9 (1.0) 6.8 (1.0) 
Oxaprozin (GDS) 220 15 21 98-230 [28] 7.9 (2,5) 8.2 (2.5) 
Flunixin (S) 252 23 20 
Key: RSD, relative standard deviation; MNA, 6-methoxy-2-naphthylacetic acid; SC, Sigma Chemical, St. Louis, MO; SB, SmithKline Beecham, 
Philadelphia, PA; MP, McNeil Pharmaceutical., Radtan, N J; U, Upjohn, Kalamazoo, MI; EL, Eli Lilly, Indianapolis, IN; GDS, G. D. Searle, Skokie, IL; S, 
Schering, Kenilworth, NJ. 
~Drug level at which the precision was determined. 
temperature was 100°C. The mass spectrometry soft- 
ware permits programming of different orifice (cone) 
potentials and collision energies for each multiple reac- 
tion monitoring (MRM) parent/product ion transition. 
Orifice voltages and collision energies are given in 
Table 1 that produced the most abundant product ion 
for each analyte and the internal standard. During 
analysis, each parent/product ion transition was mon- 
itored, in turn, for 0.07 s (dwell time) so that at least 20 
data points would be collected for each compound 
across the 30-s-wide peak to enable reproducible inte- 
gration. Argon collision-induced dissociation (CID) gas 
cell pressures of between 2.1 × 10- 3 and 2.4 × 10 3 mbar 
produced the best sensitivity. Q1 and Q2 were operated at 
unit mass resolution (10°/, peak valley). The mass spec- 
trometer was calibrated aily, according to manufactur- 
er's instructions, with a mixture of NaI and CsI. 
After addition of Flunixin internal standard (50 
/zg/50/xL) to each 250-/~L serum sample, proteins were 
precipitated by addition of 500 ~L of CH3CN while 
vortexing for 5 to 10 s. Samples were then centrifuged at 
approximately 3000 rpm for 5 min and the supernatant 
solution was transferred to brown (indomethacin is 
light sensitive) autosampler vials for analysis. 
Results and D iscuss ion  
An MRM method was constructed with one product ion 
resulting; from the (M-H) parent for each analyte and 
the internal standard, as shown in Table 1. A number of 
different solvent systems containing volatile buffers 
were compared to produce optimum Q1 sensitivity in 
the ES] mode. As expected [8], mobile phases with basic 
pH produced the most abundant (M-H)  ions for each 
analyte. Mobile phases containing some methanol or 
n-propanol produced more abundant ions than those 
containing only CH3CN/H20 adjusted to basic pH. 
Optimum overall sensitivity was obtained using the 
mobile phase described. It was necessary to prepare 
dilute NH4OH solution daily to obtain reproducible 
results. 
The method used by the autosampler to inject sam- 
ples and the amount of sample injected was found to be 
critical. The standard injection used by the autosampler 
produced what appeared to be two separate peaks. 
Modification of this program to include a,~piration of 8 
/~L of air followed by aspiration of an 8-/zL sample with 
subsequent injection of the air followed by the sample 
produced a single peak with tile best sensitivity and 
reproducibility. We believe the air bubble helps main- 
tain the integrity of the sample as it moves through the 
tubing to the mass spectrometer in the same manner in 
which air bubbles were used in old style autoanalyzers 
to separate samples. 
The type of tubing used to connect he autosampler 
to the MS/MS was found to be important. The use of 
fused silica lined PEEK tubing resulted in losses of 
NSAIDS, which may have been be due to adsorption 
[10]. PEEK tubing was found to produce acceptable 
results. The slight elevation of baseline total ion current 
after injection of levels above 100/~g/mL may be have 
been due to gradual bleeding of analytes into the MS 
which was adsorbed on to stainless steel or PEEK 
tubing [10]. 
Quantitation of each analyte was accomplished by 
determination of the ratio of product ion areas for each 
analyte to product :ion areas of the internal standard. 
'The ratio obtained for each analyte, in unknown sam- 
ples, was then compared with those ratios obtained for 
spiked standards. The calibration curve [a+b(1/x)+ 
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c (1 /x )  2 = y; x = concentration and y = ion area ratio] 
was fitted to s tandard data instead of a s imple l inear 
equation to better est imate low concentration data. A 
coefficient of determinat ion of 0.999 was found for all 
analytes over the range 0.2-100/~g/mL. 
The method sensitivity, precision, accuracy, and re- 
covery were determined for each analyte to verify the 
method usefulness as an exclusion screen. The sensitiv- 
ity required var ied by analyte depending on the ex- 
pected normal  serum range dur ing routine use. These 
data are presented for indiv idual  analytes in Table 1. To 
evaluate the method,  blank serum was fortif ied with 
equal amounts of each analyte at var ious levels and 
vortexed. After addi t ion of internal standard,  b lank and 
fortified serum samples were vortexed pr ior  to protein 
precipitat ion and analysis. The l imit of detection was 
found to be below 0 .2 /~g/mL for all analytes and was 
not adversely affected by 250 consecutive analyses. The 
presence of each analyte at 50 ~g/mL did not adversely 
affect the quantitat ion of the other analytes at a level of 
1.0 /~g/mL. The within run and between run relative 
standard deviat ion (RSD), presented in Table 1, was 
determined from single analysis of multiple, indepen- 
dent ly prepared control samples at the levels indicated. 
New blanks, standards,  and controls were used to 
determine between run (usual ly different day) repro- 
ducibil ity. The recovery of all analytes was greater than 
45% at the l imit of detection. 
Conclusions 
This direct injection ESI-MS/MS method permits  the 
s imultaneous determinat ion of 14 NSAIDS with mini-  
mal sample preparat ion.  We have demonstrated its 
uti l ity as an exclusion screen to monitor  for routine use 
of these drugs by patients involved in clinical trials. For 
use in the analysis of other drugs in serum with lower 
normal  ranges, improved sensitivities could be 
achieved by evaporat ion of the supernatant  solution 
obtained dur ing protein precipitat ion or by extraction. 
Complete method val idat ion wil l  be the subject of 
future research. 
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